SEC Tracker
Get the app
ELOX · XBRL financial data

Eloxx Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ELOX's year ends in late December)

In thousands of dollarsSep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022†Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue—————————year only——
General and administrative5,0353,718*3,0542,6452,2622,731*1,9951,8022,387year only2,1361,610
Total operating expenses10,24511,630*10,95310,2967,1426,028*5,4834,1403,637year only3,7954,450
Operating income (loss)(10,245)(11,630)*(10,953)(10,296)(7,142)(6,028)*(5,483)(4,140)(3,637)year only(3,795)(4,450)
Interest expense——————————100100
Other income (expense)360(460)*(667)(322)(366)(291)*(747)(201)45year only41(52)
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(9,885)(12,090)*(11,620)(10,618)(7,508)(6,319)*(6,230)(4,341)(3,592)year only(3,754)(4,502)
Earnings per share, basic USD per share(0.11)—(5.36)(0.12)(0.09)—(2.88)(1.96)(1.31)—(0.08)(0.66)
Earnings per share, diluted USD per share(0.11)—(5.36)(0.12)(0.09)—(2.88)(1.96)(1.31)—(0.08)(0.66)
Weighted average shares, basic thousands of shares86,209—2,16686,65486,656—2,1662,2122,748—48,2106,789
Weighted average shares, diluted thousands of shares86,209—2,16686,65486,656—2,1662,2122,748—48,2106,789
  • † Share count changed about 1/40 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (ELOX's year ends in late December)

In thousands of dollarsSep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022†Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents52,43242,26839,76830,04824,55419,2074,9044,3314,7754,7856,36361,960
Prepaid and other current assets8649132,0821,2818546611,2388416354792,1341,422
Total current assets53,54243,48042,14731,59225,67120,1296,4035,3825,6295,2708,50363,388
Property and equipment, net2242162061902151691431301070——
Right-of-use asset1,6171,4431,2651,1599938256544813060——
Total assets55,38345,13943,61832,94126,87921,1237,2005,9936,0425,2708,50363,388
Accounts payable2,5091,3792,9031,9341,5953,0202,4343,1213,1342,7133,0283,028
Accrued liabilities2,6114,1964,6314,8704,5182,7992,2302,7522,4421,6131,2362,047
Current portion of long-term debt—0—1,1252,5303,9801,5362,2762,8191,00000
Total current liabilities9,5109,95519,17419,50421,68023,09119,46021,25123,46617,17716,08716,968
Long-term debt11,91111,99612,12011,1299,8638,5574,0273,3342,6210——
Lease liability, non-current9648046384963181356430——
Total liabilities22,38522,75531,93231,12931,86131,78323,49324,58926,09017,177——
Accumulated deficit(226,233)(238,323)(249,943)(260,561)(268,069)(274,388)(280,618)(284,959)(288,551)(300,580)(304,334)(308,836)
Total stockholders' equity32,99822,38411,6861,812(4,982)(10,660)(16,293)(18,596)(20,048)(11,907)(7,584)46,420
Total liabilities and equity55,38345,13943,61832,94126,87921,1237,2005,9936,0425,2708,50363,388
Common shares outstanding (cover page) thousands of shares86,25286,65386,65386,65686,6562,1662,1662,7533,1435,0727,5744,036
  • † Share count changed about 1/40 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (ELOX's year ends in late December)

In thousands of dollarsSep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022†Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(9,885)(12,090)*(11,620)(10,618)(7,508)(6,319)*(6,230)(4,341)(3,592)year only(3,754)(4,502)
Stock-based compensation2,224*1,600*922744*714*641*597610*418*year only4695*
Net cash from operating activities(7,588)*(9,931)*(9,491)(9,747)*(6,946)*(5,661)*(6,814)(2,066)*(3,450)*year only(5,453)(4,789)*
Purchases of property and equipment—20*117*48*0*00*0*———
Net cash from investing activities(69)*(20)*(11)(7)*(48)*0*1114*233*year only——
Proceeds from issuing common stock0*0*——0*0*—1,4281,722year only——
Proceeds from long-term debt—(36)*———0*———year only00*
Net cash from financing activities3,355*(160)*7,0000*1,500*312*(7,500)1,428*3,670*year only7,03160,386*
Net change in cash(4,302)*(10,111)*(2,502)(9,754)*(5,494)*(5,349)*(14,303)(624)*453*year only1,57855,597*
  • † Share count changed about 1/40 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Eloxx Pharmaceuticals61,960not reported(4,789)*4.0M12.9 quarters 10-QJun 30, 2026
NovAccess Global210*(55)*61.7M0.4 quarters 10-KSep 30, 2024
Bioadaptives295(44)*196.9M0.7 quarters 10-QJun 30, 2026
CNBX Pharmaceuticals9.50(48)*1.6B0.2 quarters 10-QMay 31, 2026
Avenue Therapeutics1,9420(475)*3.3M4.1 quarters 10-QJun 30, 2026
Emmaus Life Sciences2,8086,3181,693*70.2M— 10-QJun 30, 2026
International Stem Cell1,0892,675167*8.0M— 10-QJun 30, 2026
Nutra Pharmanot reported34(251)*7.2B0.1 quarters 10-QJun 30, 2026
Mosaic ImmunoEngineering0not reported(0)*7.2M0.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.